ClinicalTrials.gg
RecruitingNCT07296458Updated Nov 2, 2026

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

A Phase 3 interventional study of Fenofibrate and UDCA (Ursodeoxycholic acid) in Primary Biliary Cholangitis (PBC), sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Xijing Hospital of Digestive Diseases · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 2, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary — 7 open to participants now, 9 under way, 8 of them phase 3. Fenofibrate · Liver Cirrhosis, Biliary.

Planned enrollment
5th of 13
132 · median 117
Started
2025
with 1 other
Phase 3
6 of 13
5 open now
Registered
13th of 13
by date
Lead sponsor
9 of 13
Xijing Hospital of Digestive Diseases

Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 13th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

7 of the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the drug Fenofibrate works to treat adults with a liver disease called Primary Biliary Cholangitis (PBC) who have not received previous treatment. It will also learn about the safety of Fenofibrate. The main questions it aims to answer are:

Is Fenofibrate better at helping the liver return to normal function (measured by a blood test called ALP) than the standard medication, Ursodeoxycholic What kind of medical problems do participants have when taking Fenofibrate compared to those taking UDCA?

Researchers will compare Fenofibrate to the active drug UDCA (the current standard treatment) to see which one works better.**

Participants will:

Be randomly assigned to take either Fenofibrate plus a UDCA placebo, or UDCA plus a Fenofibrate placebo, every day for 12 months. (Neither they nor their doctor will know which group they are in.) Visit the clinic 5 times over the year (at 1, 3, 6, 9, and 12 months) for check-ups, blood tests, and questionnaires.

Undergo a special scan (like FibroScan) to measure liver stiffness at some visits.

Be encouraged to have a liver biopsy at the start and end of the study to provide detailed information about liver health (this is optional).

03

Conditions studied

  • Primary Biliary Cholangitis (PBC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily join the group and be able to understand and sign the form;
  2. Age: 18 years old or above and below 75 years old;
  3. The diagnosis of primary biliary cholangitis follows the AASLD international diagnostic and treatment guidelines (meeting two of the following three criteria: positive AMA or gp210, sp100; elevated serum ALP; pathological manifestations of non-suppurative cholangitis and interlobular bile duct destruction);
  4. The patient did not receive UDCA and fenofibrate treatment in the 6 months before enrollment, and ALP was greater than the (ULN).

Exclusion criteria

Exclusion Criteria:

  1. Combined liver diseases caused by other factors: including viral hepatitis, chronic alcoholic hepatitis, steatohepatitis, drug-induced hepatitis, hepatitis, primary sclerosing cholangitis, etc;
  2. Pregnant women, lactating women, or those who plan to give birth during the study period;
  3. Individuals who are allergic to fenofibrate or ursodeoxycholic acid;
  4. At the time of diagnosis or in the past, there have been variceal bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, hepatocellular carcinoma, and hepatorenal syndrome;
  5. Individuals with a history of severe diseases or functional failures in the heart, cerebrovascular system, kidneys, respiratory system, as well as mental illnesses (including those caused by alcohol and drug abuse);
  6. Transaminase greater than 5×, or total greater than 3×ULN;
  7. Creatinine level greater than 1.5×ULN;
  8. (GFR) ≤ 45 mL/min/1.73 m2;
  9. (INR) ≥ 1.5 (for patients undergoing anticoagulant therapy, an INR value within the therapeutic target range is sufficient);
  10. Subjects who have received treatment with obeticholic acid and other fibrates (such as gemfibrozil, bezafibrate, pemafibrate, Elafibranor, Seladelpar, Lanifibranor, Saroglitizar, etc.) within the previous 6 weeks prior to screening;
  11. Screening for individuals who have taken colchicine, methotrexate, azathioprine, or undergone systemic hormone therapy for more than 2 weeks within the previous 2 months;
  12. Is currently undergoing treatment with (such as cyclosporine, tacrolimus, and related biologics);
  13. Plan to receive organ transplantation or have already undergone organ transplantation;
  14. Clear history of infection or HIV antibody positive during the screening period;
  15. Screen for individuals with a clear history of malignant tumor or anti-tumor treatment within the previous 2 years;
  16. Other situations that researchers judge as unsuitable for enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Fenofibrate

    Drug: Fenofibrate

  • Active comparator
    UDCA

    Drug: UDCA (Ursodeoxycholic acid)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Normal ALP level

    Time frame: at 12 months

Secondary outcomes

  1. Percentage of Participants with both ALP and total bilirubin normalisation

    Time frame: 12 months

  2. Percentage of participants with ALP normalization

    Time frame: 1, 3, 6, and 9 months of treatment

  3. Absolute and relative changes in ALP compared to baseline

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  4. Changes in ALT compared to baseline

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  5. Changes in AST compared to baseline

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  6. Changes in GGT compared to baseline

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  7. Changes in TB compared to baseline

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  8. Changes in itch NRS compared to baseline

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  9. Changes in liver stiffness compared to baseline

    FibroScan was used to detect the liver stiffness , and the stiffness values before and after treatment were compared

    Time frame: 1, 3, 6, 9, and 12 months of treatment

  10. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 22, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Sun Yat-sen Memorial Hospital · Guangzhou, China
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added
    Show site
    • Sun Yat-sen Memorial Hospital · Guangzhou, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07296458
Lead sponsor
Xijing Hospital of Digestive Diseases
Responsible party
Han Ying (Professor, Xijing Hospital of Digestive Diseases) — Principal investigator
First posted
Dec 22, 2025
Start date
Dec 15, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenofibrate

Start the discussion